Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Molecular and Clinical Oncology|March 22, 2016
Efficacy of first-line erlotinib in non-small cell lung cancer patients undergoing dose reduction and those with a low body surface area: A population-based observational study by the Ibaraki Thoracic Integrative (POSITIVE) Research GroupMasaharu Inagaki, Yoko Shinohara, Takayuki Kaburagi, et al.
Molecular and Clinical Oncology|December 7, 2020
A population-based study of outcomes in patients with surgically resected non-small cell lung cancer with anaplastic lymphoma kinase-rearranged mutations: A matched-pair studyMasaharu Inagaki, Hideo Ichimura, Shingo Usui, et al.
Molecular and Clinical Oncology|June 11, 2016
S-1-containing chemotherapy for patients with non-small-cell lung cancer: A population-based observational study by the Ibaraki thoracic integrative (POSITIVE) research groupMasaharu Inagaki, Yoko Shinohara, Takayuki Kaburagi, et al.
Medical Oncology (Northwood, London, England)|November 1, 2008
A population-based study of gefitinib in patients with non-small cell lung cancerKenji Hayashibara, Hiroaki Satoh, Yoko Shinohara, et al.
Anticancer Research|April 30, 2022
Prognostic Implication of PD-L1 Expression on Osimertinib Treatment for <i>EGFR</i>-mutated Non-small Cell Lung CancerToshihiro Shiozawa, Takeshi Numata, Tomohiro Tamura, et al.
Oncology Letters|February 20, 2013
Observational study on the efficacy and safety of erlotinib in patients with non-small cell lung cancerTakayuki Kaburagi, Hiroaki Satoh, Kenji Hayashihara, et al.
Medical Oncology (Northwood, London, England)|November 3, 2012
Bevacizumab-containing chemotherapy for non-small cell lung cancer patients: a population-based observational study by the Ibaraki thoracic integrative (POSITIVE) research groupHiroyuki Nakamura, Hiroaki Satoh, Takayuki Kaburagi, et al.
Anticancer Research|May 2, 2018
Acquired <i>EGFR</i> T790M Mutation After Relapse Following EGFR-TKI Therapy: A Population-based Multi-institutional StudyTakayuki Kaburagi, Moriyuki Kiyoshima, Takeshi Nawa, et al.
Molecular and Clinical Oncology|March 21, 2014
Erlotinib for elderly patients with non-small-cell lung cancer: Subset analysis from a population-based observational study by the Ibaraki Thoracic Integrative (POSITIVE) Research GroupKoichi Kurishima, Hiroaki Satoh, Takayuki Kaburagi, et al.
Anticancer Research|February 5, 2020
Real Clinical Practice in ALK-rearranged NSCLC Patients: A Retrospective Observational StudyShinichiro Okauchi, Takeshi Numata, Takeshi Nawa, et al.
Pageof 6